Japan’s Astellas Pharma is entering the immuno-oncology field, teaming up with privately-held Potenza Therapeutics. The companies announced that they have entered into an exclusive research and development collaboration with a goal of advancing a portfolio consisting of programs with novel mechanisms of action targeting immune checkpoint pathways, co-stimulatory signals and …